Physician profile
Stephen Matlock
NPI 1811494727
$2,766.45
in general payments reported to CMS, 2019-2025
16 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $597 · 2024: $799 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.68 | 2023-2025 | |
| Organogenesis INC. | $655.62 | 2023-2025 | Nushield, Via Matrix, Novachor |
| E.R. Squibb & Sons, L.L.C. | $333.22 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $185.45 | 2023-2025 | |
| Kerecis Limited | $172.85 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Lilly USA, LLC | $137.59 | 2022-2024 | Olumiant, Taltz |
| Ucb, INC. | $114.59 | 2022-2025 | Cimzia, Bimzelx |
| Amgen INC. | $84.96 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $61.89 | 2023-2024 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $38.24 | 2024 | Vtama |
| Janssen Biotech, INC. | $27.07 | 2023 | Tremfya |
| Convatec INC. | $26.31 | 2024 | |
| Leo Pharma INC. | $24.34 | 2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.62 | 2024 | Arazlo |
| Fresenius Kabi USA, LLC | $15.63 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $14.39 | 2024 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Matlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.